Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
See how your peers are using EXPAREL for optimal pain coverage
EXPAREL is a cost-effective option for postsurgical pain management both in the hospital and in outpatient settings
Medical center in California
47% lower opioid consumption during the hospital stay*â€
16.9 hours shorter LOS
$7804 lower hospital charges
Medical center in Illinois
Significantly better pain control (P <0.01) 4, 8, 12, 16, and 24 hours postsurgery‡
67% patients discharged home after 1 day
Medical center in New York
Fewer total opioids used after surgery vs catheter and control groups (mg)*§
0.9 to 1.4 days shorter LOS
Medical center in Minnesota
Significantly better pain control (P=0.02) 24 hours postsurgery‡
71% fewer total opioids used postsurgery (mg)*¶
1.6 days shorter LOS postsurgery
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials.
†Opioid consumption was noted and converted to MED per hour of hospital stay.1
‡All pain was measured with the visual analog scale.2,4
§Opioid consumption was measured using IV morphine equivalent (mg).3
¶Parenteral and oral opioid intake was converted into oral morphine equivalents (mg) using standardized calculations.4
Multimodal approaches with or without ERAS protocols have demonstrated benefits in breast surgeries.
Protocol implementation can positively impact recovery4
Retrospective analysis comparing an ERP with PCA of ketorolac and an EXPAREL TAP block (n=42) with historical controls (n=49) in patients undergoing deep inferior epigastric perforator or free transversus rectus abdominis myocutaneous flap breast reconstruction.
*Opioid intake measured in MED (mg).
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ERP, enhanced recovery pathway; LOS, length of stay; MED, morphine equivalent dosing; PACU, postanesthesia care unit; PCA, patient-controlled analgesia; POD, postoperative day; TAP, transversus abdominis plane.
Retrospective study comparing the efficacy of EXPAREL as a TAP block and local infiltration as part of an ERAS pathway (n=49) with a historical cohort of patients who received traditional care after surgery (n=51).
*Opioid intake measured in MED (mg).
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ERAS, enhanced recovery after surgery; LOS, length of stay; MED, morphine equivalent dosing; TAP, transversus abdominis plane.
The Breast Reconstruction Advisory Group and ERAS Society support the use of opioid-minimizing pain management strategies
Breast Construction Advisory Group
2015 Guidelines
The authors propose an opioid-sparing multimodal analgesic clinical pathway for 4 common breast procedures...6
ERAS Society
Breast Reconstruction 2017
Strong recommendation for the use of multimodal ‘opioid-sparing postsurgical pain bupivacaine regimens, noting that ‘a single injection of liposomal bupivacaine lasts for several days, potentially avoiding the need for catheter-based infusions.’7
ERAS, enhanced recovery after surgery.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.